Dr. Tole is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
117 Encina Commons
Stanford University
Stanford, CA 94305Phone+1 650-723-2217
Education & Training
University of California (San Francisco)Residency, Internal Medicine, 1999 - 2002- University of California San Francisco School of MedicineClass of 1999
Clinical Trials
Publications & Presentations
PubMed
- 57 citationsEtrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, ran...Laurent Peyrin-Biroulet, Ailsa Hart, Peter Bossuyt, Millie D. Long, Matthieu Allez
The Lancet. Gastroenterology & Hepatology. 2021-11-17 - 50 citationsEtrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.Silvio Danese, Jean-Frederic Colombel, Milan Lukas, Javier P Gisbert, Geert R. D'Haens
The Lancet. Gastroenterology & Hepatology. 2021-11-16 - 42 citationsEtrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3...Severine Vermeire, Peter L. Lakatos, Timothy Ritter, Stephen B. Hanauer, Brian Bressler
The Lancet. Gastroenterology & Hepatology. 2021-11-16
Press Mentions
HMN 2024: FDA Grants Orphan Drug Designation to Potential Treatment of STXBP1 Developmental and Epileptic EncephalopathyNovember 17th, 2024- Female Founded and Funded Capsida Taps Swati Tole as Chief Medical OfficerJune 1st, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
